Evidence map›Paper›PMID 37654604›Full record

ArticleFrontiers in pharmacology2023

Tamaeh Monteiro-Alfredo, Jéssica Maurino Dos Santos, Kátia Ávila Antunes, Janielle Cunha, Debora da Silva Baldivia, Ana Salomé Pires, Inês Marques, Ana Margarida Abrantes, Maria Filomena Botelho, Lúcia Monteiro and 8 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in pharmacology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
2.6field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Pharmaceuticals (Basel, Switzerland) · 2025
    Article
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 2 institutions in 2 countries.

Tamaeh Monteiro-AlfredoResearch Group on Biotechnology and Bioprospection Applied to Metabolism and Cancer (GEBBAM), Federal University of Grande Dourados, Dourados, Brazil.
Jéssica Maurino Dos SantosResearch Group on Biotechnology and Bioprospection Applied to Metabolism and Cancer (GEBBAM), Federal University of Grande Dourados, Dourados, Brazil.
Kátia Ávila AntunesResearch Group on Biotechnology and Bioprospection Applied to Metabolism and Cancer (GEBBAM), Federal University of Grande Dourados, Dourados, Brazil.
Janielle CunhaResearch Group on Biotechnology and Bioprospection Applied to Metabolism and Cancer (GEBBAM), Federal University of Grande Dourados, Dourados, Brazil.
Debora da Silva BaldiviaResearch Group on Biotechnology and Bioprospection Applied to Metabolism and Cancer (GEBBAM), Federal University of Grande Dourados, Dourados, Brazil.
Ana Salomé PiresClinical Academic Center of Coimbra (CACC), University of Coimbra, Coimbra, Portugal.
Inês MarquesClinical Academic Center of Coimbra (CACC), University of Coimbra, Coimbra, Portugal.
Ana Margarida AbrantesClinical Academic Center of Coimbra (CACC), University of Coimbra, Coimbra, Portugal.
Maria Filomena BotelhoClinical Academic Center of Coimbra (CACC), University of Coimbra, Coimbra, Portugal.
Lúcia MonteiroFaculty of Medicine, Coimbra Institute for Clinical and Biomedical Research (iCBR) Area of Environment Genetics and Oncobiology (CIMAGO), Institute of Biophysics, University Coimbra, Coimbra, Portugal.
Ana Cristina GonçalvesFaculty of Medicine, Coimbra Institute for Clinical and Biomedical Research (iCBR), University of Coimbra, Coimbra, Portugal.
Wellington Henrique BotelhoResearch Group on Biotechnology and Bioprospection Applied to Metabolism and Cancer (GEBBAM), Federal University of Grande Dourados, Dourados, Brazil.
Ana Paula de Araújo BoletiResearch Group on Biotechnology and Bioprospection Applied to Metabolism and Cancer (GEBBAM), Federal University of Grande Dourados, Dourados, Brazil.
Célia CabralFaculty of Medicine, Coimbra Institute for Clinical and Biomedical Research (iCBR), University of Coimbra, Coimbra, Portugal.
Paulo J OliveiraCNC-Center for Neuroscience and Cell Biology, Center for Innovative Biomedicine and Biotechnology, University of Coimbra, Coimbra, Portugal.
Edson Lucas Dos SantosResearch Group on Biotechnology and Bioprospection Applied to Metabolism and Cancer (GEBBAM), Federal University of Grande Dourados, Dourados, Brazil.
Paulo MatafomeFaculty of Medicine, Institute of Physiology, University of Coimbra, Coimbra, Portugal.
Kely de Picoli SouzaResearch Group on Biotechnology and Bioprospection Applied to Metabolism and Cancer (GEBBAM), Federal University of Grande Dourados, Dourados, Brazil.
University of Coimbra · PTUniversidade Federal da Grande Dourados · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Doxorubicin (Dox) is a chemotherapeutic agent widely used in the clinic, whose side effects include cardiotoxicity, associated with decreased antioxidant defenses and increased oxidative stress. The association of Dox with natural antioxidants can extend its use if not interfering with its pharmacological potential. In this study, we aimed to understand the effects and mechanisms of the aqueous extract of

Indexed as

antioxidantbocaiúvaBrazilian cerradochemotherapy side-effectsmacaúbaoxidative stress

Identifiers

PMID37654604
PMCPMC10466431
OpenAlexW4385951001

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.